New target for Oncoceutics' GPCR-targeting compounds

Oncoceutics' compounds increase mitochondrial protease activity to kill cancer

Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease.

Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including dopamine receptors. Oncoceutics’ management team told BioCentury its lead product,

Read the full 445 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE